PART I Overview We are a dermatologist-founded, late clinical-stage biopharmaceutical company, or the Company, we, us, or our, focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Our initial focus is developing better treatments for PHL, a condition affecting approximately 50 million men and 30 million women in the United States. Current PHL treatment options are limited and therefore are consistentl...
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-30 | 2025-12-31 | 0001827635-26-000013 | EDGAR | 110K words |
No 10-Q filings indexed.
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-30 | 0001827635-26-000010 | EDGAR | 3K words |
| 2026-02-05 | 0001628280-26-005800 | EDGAR | — |
5 total filings indexed. 2 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001827635 |
| Ticker | MANE |
| Exchange | NYSE |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.veradermics.com |
| Listed | 2026-02-04 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report